Clinical Trials
38 trialsNCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT06207799 2026-02-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07188090 2025-11-28
HSCT
Thomas Jefferson University
Phase 2 Recruiting
NCT01526096 2025-11-05
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
Phase 1 Completed
NCT01186224 2025-03-17
PHANTASTIC
University of Liverpool
Phase NA Completed
NCT04552743 2022-09-10
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Stanford University
Phase 2 Completed
NCT02703779 2021-06-18
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
University of Kansas Medical Center
Phase 2 Completed
NCT01753453 2021-02-23
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
Sanofi
Phase 2 Completed
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed
NCT02682953 2019-12-11
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT01547806 2018-03-07
Collection of Transplant Stem Cells for Plasma Cell Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03244930 2017-08-10
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT01339572 2017-08-01
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
University of Florida
Phase 2 Completed
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT01076270 2017-06-28
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase NA Terminated
NCT00241358 2017-06-06
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
Phase 1/2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT01610999 2017-05-09
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Tufts Medical Center
Phase 1 Terminated
NCT02221479 2015-08-04
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Sanofi
Phase 2 Completed
NCT00998049 2015-05-14
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Mayo Clinic
Phase 2 Completed
NCT00395967 2015-05-01
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Sanofi
Phase 2 Terminated
NCT01095757 2014-09-29
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Emory University
Phase 2 Completed
NCT01301963 2014-08-06
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Case Comprehensive Cancer Center
Phase 3 Terminated
NCT00901225 2014-05-07
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
Phase 2 Completed
NCT01220375 2014-04-17
PAV
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT00103662 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Sanofi
Phase 3 Completed
NCT00322387 2014-03-13
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Sanofi
Phase 2 Completed
NCT00322491 2014-03-13
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00322842 2014-03-13
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Sanofi
Phase 2 Completed
NCT00396331 2014-03-13
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
Sanofi
Phase 2 Completed
NCT00396383 2014-03-13
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
Sanofi
Phase 2 Terminated
NCT00396266 2014-03-07
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Sanofi
Phase 2 Completed
NCT00665314 2014-02-11
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
Sanofi
Phase 2 Completed
NCT01037517 2013-10-31
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
CancerCare Manitoba
Phase 2 Completed
NCT01074060 2013-02-15
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT01042717 2011-09-27
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Shi, Patricia, M.D.
Phase NA Unknown